Τίτλος:
A phase II study of sequential docetaxel and gemcitabine followed by
docetaxel and carboplatin as first-line therapy for non-small cell lung
cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Our study involves a preliminary phase II trial, which evaluates the
activity, feasibility and tolerability of a sequential combination of
docetaxel and gemcitabine followed by docetaxel and carboplatin, as
first-line treatment for inoperable NSCLC. Twenty-six chemo-naive
patients aged less than 75 years with histologically or cytologically
confirmed unresectable stage IIIB, IV or relapsed post-operative
metastatic NSCLC were included in the study. Gemcitabine 1,250 mg/m(2)
was administered and was followed by docetaxel 65 mg/m(2). Treatment was
administered on days 1 and 14 in a 28-day cycle for three consecutive
cycles. If patients had no progressive disease after three cycles of
chemotherapy, they received another three cycles of docetaxel 65 mg/m(2)
followed by carboplatin AUC5 on day 1 in a 21-day cycle. Recombinant
human granocyte colony-stimulating factor (rhG-CSF) was given
prophylactically. In addition, all patients received standard pre- and
post- treatment with oral dexamethasone. Response rates at three cycles
were: 19% achieved a partial response (PR), 46% had stable disease
(SD) and 23% had progressive disease. At six cycles, 8% of the
patients maintained PR, 19% showed SD and 35% had progressive disease.
The median time-to-disease progression was 6 months. The median survival
time of patients was 10 months while, at the end of the first year, the
patients who managed to get through the complete therapy (20 patients)
had a survival rate of 38%. This detailed analysis of 20 patients
showed that 80% of the patients survived for up to 6 months, 38% up to
12 months and 19% for more than a year. The only risk factor associated
with the hazard of death among the factors studied was the performance
status of the patients. Patients with PS = 0 presented a median survival
time of 13 months and those with PS = 1, it was only 9 months.
Non-haematological and haematological toxic effects were generally mild
to moderate and entirely manageable.
Συγγραφείς:
Karapanagiotou, Eleni M.
Charpidou, Adrianni
Tzannou, Ifigenia
and Dilana, Kalliopi
Kotteas, Elias
Tourkantonis, Ioannis and
Kosmas, Epaminondas
Provata, Aspasia
Syrigos, Kostas
Περιοδικό:
Medical Oncology
Εκδότης:
Humana Press Inc.
Λέξεις-κλειδιά:
NSCLC therapy; First-line therapy; Doublet regimens; Combination
chemotherapy; Docetaxel; Gemcitabine; Carboplatin
DOI:
10.1007/s12032-007-9036-9
